Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 7/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600425 | 0.94 | NTRK1 (0.49) | ALKRIPK1NTRK1ALDH1A1HTT | |
| SCHEMBL14387471 | 0.87 | ALK (0.59) | ALKNTRK1HPGD | |
| SCHEMBL1601019 | 0.86 | ALK (0.76) | ALK | |
| SCHEMBL1601018 | 0.86 | ALK (0.76) | ALK | |
| SCHEMBL19908262 | 0.84 | ALK (0.54) | ALKRIPK1NTRK1ALDH1A1HTT | |
| SCHEMBL1602277 | 0.78 | ALK (0.66) | ALKNTRK1 | |
| SCHEMBL19908264 | 0.78 | AR (0.38) | ALKNTRK1ALDH1A1ROCK2 | |
| SCHEMBL1601642 | 0.78 | ALK (0.51) | ALKRIPK1NTRK1 | |
| SCHEMBL1602786 | 0.77 | AR (0.37) | ALKNTRK1ROCK2 | |
| SCHEMBL1600401 | 0.77 | ALK (0.70) | ALKNTRK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091951-B1 | PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2018-02-28 | — | — | EP | disclosed |